Burosumab

(Crysvita®)

Burosumab

Drug updated on 11/16/2023

Dosage FormInjectable (subcutaneous; 10 mg/mL, 20 mg/mL, 30 mg/mL)
Drug ClassFibroblast growth factor blocking antibodies
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • For the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 6 months of age and older.
  • For the treatment of FGF23-related hypophosphatemia in tumor induced osteomalacia (TIO) associated with phosphaturic mesenchymal tumors that cannot be curatively resected or localized in adult and pediatric patients 2 years of age and older.